$MMED

MiniMed Group, Inc. (MMED) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0002062583 0002062583 2026-07-30 2026-07-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor

Medtronic (NYSE: MDT) is spinning off its diabetes business into MiniMed Group (NASDAQ: MMED), which plans an IPO of 28 million shares at $25 to $28, valuing it near $7.9B. MiniMed targets a full-stack insulin pump and CGM ecosystem. The diabetes unit reported $2.7B revenue in FY2025 and losses tied to R&D. Risks include competition from Dexcom, Abbott, Insulet and Tandem.

MiniMed (Nasdaq: MMED) said Medicare and Medicare Advantage beneficiaries can now access its MiniMed Flex insulin pump with the latest sensor portfolio. The compact app-controlled pump holds 300 units and uses SmartGuard technology that adjusts insulin every five minutes, day and night. MiniMed cited real-world ADA 2026 data for its MiniMed 780G system and said Instinct sensor availability is later this summer.

MiniMed Group, Inc. (MMED) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0002062583 0002062583 2026-06-25 2026-06-25 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor

MiniMed Group shares rose 14.88% to $14.13 on Wednesday, after the company reported stronger Q4 revenue and a fiscal 2027 outlook. The company said Q4 revenue increased to $837 million from $724 million, despite a wider net loss of $183 million. It projected about 10% organic revenue growth for 2027 and an adjusted EBITDA margin near 16%.

MiniMed (NASDAQ: MMED) said it expanded its agreement with Abbott to commercialize integrated dual glucose-ketone sensors for exclusive use with MiniMed smart dosing systems. The sensors, built on the Instinct platform, aim to detect rising ketones earlier to help reduce diabetic ketoacidosis risk. Abbott’s dual system has CE Mark and is under FDA review; further milestones are expected.

MiniMed (Nasdaq: MMED) reported Q4 net sales of $837 million, up 15.6% reported and 8.7% organic, and full FY26 net sales of $3.102 billion, up 14.2% reported and 8.0% organic, according to the company. It cited FDA clearance for MiniMed Flex and CE Mark for Instinct, plus global launch of MiniMed Go. For FY27, it expects ~10% organic revenue growth and ~16% adjusted EBITDA margin.

Keybanc analyst Sophie Karp initiated coverage on NiSource Inc. (NYSE: NI) with an Overweight rating and a price target of $52. Additionally, BTIG analyst Marie Thibault began coverage on Minimed Group, Inc. (NASDAQ: MMED) with a Buy rating and a $25 price target, and HC Wainwright & Co. analyst Yi Chen initiated coverage on Envoy Medical, Inc. (NASDAQ: COCH) with a Buy rating and a $2.5 price target. These inaugurate Tuesday's top analyst initiations, reflecting bullish outlooks for the respective companies.